What is INQOVI?

MDS can require lifelong treatment1*

Receiving treatment for MDS, including CMML, can be challenging for some patients and caregivers, requiring2-4

Icon of a hospital representing chemotherapy infusion centers

Additional travel to and from chemotherapy infusion centers or hospitals for IV infusions or subcutaneous injection

  • Visits may be long and frequent, for multiple cycles (5-7 days/cycle)3,5
Icon of a syringe representing venous access and parenteral administration

Venous access and parenteral administration4,6

*Especially in the case of transplant-ineligible patients. IV=intravenous

Cedazuridine enables oral delivery of decitabine7

INQOVI® (decitabine and cedazuridine) tablets are 1 pill, taken once daily for 5 days out of a 28-day cycle. See full dosing information here. INQOVI is a fixed-dose combination of decitabine (35 mg) and cedazuridine (100 mg), a cytidine deaminase (CDA) inhibitor that enhances oral bioavailability of decitabine and also increases its systemic exposure.

A chart depicting the mechanism of action for INQOVI A chart depicting the mechanism of action for INQOVI
  • Decitabine is a nucleoside metabolic inhibitor that is believed to exert its effects by causing DNA hypomethylation. This may restore normal function to genes that are critical for the control of cellular differentiation and proliferation
  • Nonproliferating cells are relatively insensitive to decitabine
  • CDA is an enzyme responsible for degradation of nucleosides such as decitabine into inactive metabolites, thus limiting their oral bioavailability
  • Administration of cedazuridine with decitabine increases systemic exposure of decitabine

DNMT=DNA methyltransferase.

Your patients may be appropriate for INQOVI, if they are7:

  • Diagnosed with de novo or secondary MDS, including CMML
  • Classified as intermediate- or high-risk MDS
  • Have not received prior treatment or have previously been treated

ADDITIONAL PATIENT CONSIDERATIONS:

  • Wish to take their HMA therapy in the comfort of their own home
  • Unable to have, or do not wish to have, infusion port placement
  • Do not have regular support to manage travel to the infusion center

Support for you and your patients

Taiho Oncology Patient Support™ offers personalized services. This includes insurance verification, help with medication costs, and treatment plan support.

References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096‑1107. 2. Bell JA, Galaznik A, Blazer M, et al. Economic burden of patients treated for higher‑risk myelodysplastic syndromes (HR‑MDS) in routine clinical care in the United States. PharmacoEconomics Open. 2019;3(2): 237‑245. 3. Savona MR, Odenike O, Amrein PC, et al. An oral fixed‑dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open‑label, dose‑escalation, phase 1 study. Lancet Haematol. 2019;6(4): e194‑e203. doi:10.1016/S2352‑3026(19)30030‑4. 4. Steensma DP, Komrokji RS, Stone RM, et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014;120(11):1670‑1676. 5. Vidaza [package insert]. Summit, NJ: Celgene Corporation; 2020. 6. Leveque D. Subcutaneous administration of anticancer agents. Anticancer Research. 2014;34(4):1579‑1586. 7. INQOVI. Prescribing information. Taiho Oncology Inc; 2020.

Previous Page 

Home

Next Page 

Pharmacokinetics, Efficacy & Safety